The earnings miss and widening loss are near-term negatives, but the stock's direction will hinge on upcoming regulatory catalysts for AMT-130 (FDA Type B meeting in Q2, MHRA MAA submission in Q3). Traders should watch for any FDA feedback that could derail or accelerate the path to approval, as well as the four-year AMT-130 data analysis expected in Q3 2026.
Price Chart
Executive Summary
uniQure reported Q1 2026 EPS of -$0.85, missing the consensus estimate of -$0.75 by 13.3%, and revenue of $3.6M, below the $4.5M consensus. The net loss widened to $53.5M from $43.6M a year ago, driven by a $9.2M increase in SG&A expenses. The stock may react negatively to the earnings miss and widening loss, though the company's strong cash position ($586.6M) and upcoming regulatory milestones for AMT-130 provide some offset.
Key Financial Metrics
Key Facts
- Q1 2026 EPS of -$0.85 missed consensus of -$0.75 by 13.3%
- Q1 2026 revenue of $3.6M missed consensus of $4.5M by 20%
- Net loss widened to $53.5M from $43.6M in Q1 2025
- SG&A expenses surged 84% to $20.1M from $10.9M a year ago
- Cash, cash equivalents and investment securities of $586.6M as of March 31, 2026
- Cash runway into second half of 2029
- FDA Type B meeting for AMT-130 scheduled for Q2 2026
- MAA submission for AMT-130 to UK MHRA expected in Q3 2026
- AMT-260 Phase I/IIa data from first cohort expected at Epilepsy Foundation Pipeline Conference June 18-19, 2026
- AMT-162 development discontinued after dose-limiting toxicity
Financial Impact
EPS miss of 13.3% and revenue miss of 20% vs consensus; net loss widened by $9.9M YoY
Risk Factors
- FDA may not agree that Phase I/II data plus external control are sufficient for BLA, requiring a new costly trial
- SG&A expense growth may continue as the company builds commercial infrastructure for AMT-130
- AMT-260 and AMT-191 clinical data may disappoint
- Liability from royalty financing agreement of $482.3M could pressure future cash flows
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3287519 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 2, 2026 4w ago | 8-K | $46.23 $44.47 | ▼ −3.81% | ▼ −2.85% | $23.15 (−49.92%) |
Jul 29, 2026 9w ago | 8-K | $40.07 $44.24 | ▲ +10.41% | ▲ +4.88% | $23.15 (−42.23%) |
Jul 7, 2026 12w ago | Insider Cluster | $41.41 $41.52 | ▼ −0.27% | ▲ +0.29% | $23.15 (+44.10%) |
Jul 2, 2026 13w ago | Insider Cluster | $41.81 $44.48 | ▼ −6.39% | ▼ −5.46% | $23.15 (+44.63%) |
Jul 2, 2026 13w ago | Insider Cluster | $41.81 $44.48 | ▲ +6.39% | ▲ +5.46% | $23.15 (−44.63%) |
Jul 2, 2026 13w ago | 144 | $41.81 $44.48 | ▲ +6.39% | ▲ +5.46% | $23.15 (−44.63%) |
Jun 30, 2026 13w ago | 144 | $45.17 $41.41 | ▼ −8.32% | ▼ −8.59% | $23.15 (−48.75%) |
Jun 25, 2026 14w ago | 144 | $47.51 $41.81 | ▲ +12.00% | ▲ +14.16% | $23.15 (+51.27%) |
Jun 24, 2026 14w ago | 424B5 | $49.10 $45.17 | ▼ −8.00% | ▼ −9.56% | $23.15 (−52.85%) |
Jun 24, 2026 14w ago | 144 | $49.10 $45.17 | ▼ −8.00% | ▼ −9.56% | $23.15 (−52.85%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access